Monoclonal antibody · Kills target cells, directed at killer cell immunoglobulin-like receptor 3DL2 (KIR3DL2) · developed by Innate Pharma
Lacutamab is a humanized monoclonal antibody that binds KIR3DL2, a receptor expressed on certain tumor cells, including most subtypes of cutaneous T-cell lymphoma. It recruits natural killer cells and induces antibody-dependent cellular cytotoxicity to lyse KIR3DL2-expressing cells. It is studied in T-cell lymphomas, including mycosis fungoides and Sezary syndrome.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04984837 | Phase 2 | Peripheral T Cell Lymphoma | Active not recruiting | IPHA |
| NCT03902184 | Phase 2 | Lymphoma, T-Cell | Completed | IPHA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Peripheral T Cell LymphomaRelapse/RecurrenceLymphoma, T-CellLymphoma, T-Cell, CutaneousMycosis Fungoides/Sezary Syndrome
Updated Oct 18, 2026. Something wrong or missing? Report it on the IPHA page.
See IPHA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
IPHA catalysts and pipeline →